Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 6.71
KMDA's Cash to Debt is ranked higher than
66% of the 1484 Companies
in the Global Biotechnology industry.

( Industry Median: 48.31 vs. KMDA: 6.71 )
KMDA' s 10-Year Cash to Debt Range
Min: 1.32   Max: N/A
Current: 6.71

Equity to Asset 0.69
KMDA's Equity to Asset is ranked higher than
74% of the 1112 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. KMDA: 0.69 )
KMDA' s 10-Year Equity to Asset Range
Min: 0.28   Max: 0.69
Current: 0.69

0.28
0.69
F-Score: 3
Z-Score: 2.33
M-Score: -2.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -21.74
KMDA's Operating margin (%) is ranked higher than
79% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -82.48 vs. KMDA: -21.74 )
KMDA' s 10-Year Operating margin (%) Range
Min: -121.42   Max: 5.83
Current: -21.74

-121.42
5.83
Net-margin (%) -23.03
KMDA's Net-margin (%) is ranked higher than
78% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. KMDA: -23.03 )
KMDA' s 10-Year Net-margin (%) Range
Min: -170.4   Max: 0.63
Current: -23.03

-170.4
0.63
ROE (%) -19.07
KMDA's ROE (%) is ranked higher than
76% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: -28.35 vs. KMDA: -19.07 )
KMDA' s 10-Year ROE (%) Range
Min: -196.96   Max: 1.83
Current: -19.07

-196.96
1.83
ROA (%) -12.31
KMDA's ROA (%) is ranked higher than
78% of the 1489 Companies
in the Global Biotechnology industry.

( Industry Median: -22.44 vs. KMDA: -12.31 )
KMDA' s 10-Year ROA (%) Range
Min: -59.2   Max: 0.58
Current: -12.31

-59.2
0.58
ROC (Joel Greenblatt) (%) -35.43
KMDA's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 1448 Companies
in the Global Biotechnology industry.

( Industry Median: -352.58 vs. KMDA: -35.43 )
KMDA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -179.63   Max: 27.3
Current: -35.43

-179.63
27.3
Revenue Growth (3Y)(%) -2.70
KMDA's Revenue Growth (3Y)(%) is ranked higher than
74% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. KMDA: -2.70 )
KMDA' s 10-Year Revenue Growth (3Y)(%) Range
Min: -2.7   Max: 44.1
Current: -2.7

-2.7
44.1
» KMDA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

KMDA Guru Trades in Q2 2014

Jim Simons 70,265 sh (+210.91%)
John Paulson 750,000 sh (unchged)
» More
Q3 2014

KMDA Guru Trades in Q3 2014

John Paulson 750,000 sh (unchged)
Jim Simons 67,740 sh (-3.59%)
» More
Q4 2014

KMDA Guru Trades in Q4 2014

Jim Simons 123,406 sh (+82.18%)
John Paulson 739,356 sh (-1.42%)
» More
Q1 2015

KMDA Guru Trades in Q1 2015

Jim Simons 169,100 sh (+37.03%)
John Paulson 739,356 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with KMDA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 26.88
KMDA's Forward P/E is ranked higher than
88% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. KMDA: 26.88 )
N/A
P/B 1.90
KMDA's P/B is ranked higher than
89% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. KMDA: 1.90 )
KMDA' s 10-Year P/B Range
Min: 1.41   Max: 11.31
Current: 1.9

1.41
11.31
P/S 2.29
KMDA's P/S is ranked higher than
93% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 40.50 vs. KMDA: 2.29 )
KMDA' s 10-Year P/S Range
Min: 1.58   Max: 13.19
Current: 2.29

1.58
13.19
EV-to-EBIT -7.45
KMDA's EV-to-EBIT is ranked lower than
51% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. KMDA: -7.45 )
KMDA' s 10-Year EV-to-EBIT Range
Min: -173.6   Max: 591.1
Current: -7.45

-173.6
591.1
Current Ratio 3.29
KMDA's Current Ratio is ranked higher than
68% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. KMDA: 3.29 )
KMDA' s 10-Year Current Ratio Range
Min: 2.21   Max: 4.42
Current: 3.29

2.21
4.42
Quick Ratio 2.27
KMDA's Quick Ratio is ranked higher than
63% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. KMDA: 2.27 )
KMDA' s 10-Year Quick Ratio Range
Min: 1.45   Max: 3.59
Current: 2.27

1.45
3.59
Days Inventory 174.89
KMDA's Days Inventory is ranked higher than
83% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. KMDA: 174.89 )
KMDA' s 10-Year Days Inventory Range
Min: 34.72   Max: 187.18
Current: 174.89

34.72
187.18
Days Sales Outstanding 64.56
KMDA's Days Sales Outstanding is ranked higher than
83% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. KMDA: 64.56 )
KMDA' s 10-Year Days Sales Outstanding Range
Min: 69.61   Max: 97.76
Current: 64.56

69.61
97.76

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.10
KMDA's Price/Net Cash is ranked higher than
75% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 220.30 vs. KMDA: 12.10 )
KMDA' s 10-Year Price/Net Cash Range
Min: 9.82   Max: 25.84
Current: 12.1

9.82
25.84
Price/Net Current Asset Value 3.90
KMDA's Price/Net Current Asset Value is ranked higher than
89% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 46.00 vs. KMDA: 3.90 )
KMDA' s 10-Year Price/Net Current Asset Value Range
Min: 2.21   Max: 38.13
Current: 3.9

2.21
38.13
Price/Tangible Book 1.90
KMDA's Price/Tangible Book is ranked higher than
91% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 10.40 vs. KMDA: 1.90 )
KMDA' s 10-Year Price/Tangible Book Range
Min: 1.96   Max: 10.29
Current: 1.9

1.96
10.29
Price/Median PS Value 0.50
KMDA's Price/Median PS Value is ranked higher than
95% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 3.00 vs. KMDA: 0.50 )
KMDA' s 10-Year Price/Median PS Value Range
Min: 0.42   Max: 2.97
Current: 0.5

0.42
2.97
Earnings Yield (Greenblatt) -13.80
KMDA's Earnings Yield (Greenblatt) is ranked higher than
52% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. KMDA: -13.80 )
KMDA' s 10-Year Earnings Yield (Greenblatt) Range
Min: -14.1   Max: 2.6
Current: -13.8

-14.1
2.6

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:KMDA.Israel,
Kamada Ltd. develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises of Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other. Its business is segmented into two - Proprietary Product and Distribution. The Proprietary Product segment develops and manufactures plasma-derived therapeutics and market them in more than 15 countries. The Distribution segment distributes drugs manufactured by third-parties for critical use in Israel, produced from plasma or its derivative products.
» More Articles for KMDA

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlights: FMS, SNOW, KMDA, LAYN Jun 16 2014 

More From Other Websites
Kamada Reports Updated Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin to... May 20 2015
Kamada Reports Updated Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin to... May 20 2015
Kamada Reports First Quarter 2015 Financial Results May 12 2015
Kamada reports 1Q loss May 12 2015
Kamada reports 1Q loss May 12 2015
Kamada Reports First Quarter 2015 Financial Results May 12 2015
Kamada to Host First Quarter 2015 Financial Results Conference Call on May 12, 2015 May 10 2015
Kamada to Host First Quarter 2015 Financial Results Conference Call on May 12, 2015 May 08 2015
Kamada to Present Key Results from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin... May 06 2015
Kamada to Present Key Results from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin... May 06 2015
CFO Moves: E.ON, Yoox, AudioCodes, Kamada Apr 28 2015
Kamada Announces Executive Management Changes Apr 28 2015
Kamada Reports Additional Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin... Apr 22 2015
Kamada Reports Additional Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin... Apr 20 2015
Kamada Receives Allowance for Key Canadian Patent for Large Scale Production and Use of Proprietary... Apr 01 2015
Kamada Receives Allowance for Key Canadian Patent for Large Scale Production and Use of Proprietary... Apr 01 2015
Kamada Awarded European Orphan Drug Designation for Its Alpha-1 Antitrypsin to Treat... Mar 23 2015
Kamada Strengthens Leadership Team with the Addition of Vice President - Medical Director Mar 15 2015
Kamada Strengthens Leadership Team with the Addition of Vice President-Medical Director Mar 11 2015
Kamada Reports 2014 Fourth Quarter and Full Year Financial Results Feb 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK